JP2024519529A - Ｃｄ１９特異的キメラ抗原受容体ｔ細胞療法 - Google Patents

Ｃｄ１９特異的キメラ抗原受容体ｔ細胞療法 Download PDF

Info

Publication number
JP2024519529A
JP2024519529A JP2023568007A JP2023568007A JP2024519529A JP 2024519529 A JP2024519529 A JP 2024519529A JP 2023568007 A JP2023568007 A JP 2023568007A JP 2023568007 A JP2023568007 A JP 2023568007A JP 2024519529 A JP2024519529 A JP 2024519529A
Authority
JP
Japan
Prior art keywords
cells
car
seq
cell
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519529A5 (cg-RX-API-DMAC10.html
Inventor
オテロ マネル フアン
イスピッツア アルバロ ウルバノ
カプデビラ マリオナ パスカル
リベス ジョルディ ジャグエ
ゴンサレス フリオ デルガド
レイナー ジョルディ エステべ
カスティッラ マリア カスティッラ
バラド アナ ボロナット
Original Assignee
フンダシオ デ レセルカ クリニック バルセロナ－インスティテュート ディンベスティガシオンス ビオメディケス アウグスト ペイ イ スニェー
ホスピタル クリニック デ バルセロナ
ユニベルシタ デ バルセロナ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フンダシオ デ レセルカ クリニック バルセロナ－インスティテュート ディンベスティガシオンス ビオメディケス アウグスト ペイ イ スニェー, ホスピタル クリニック デ バルセロナ, ユニベルシタ デ バルセロナ filed Critical フンダシオ デ レセルカ クリニック バルセロナ－インスティテュート ディンベスティガシオンス ビオメディケス アウグスト ペイ イ スニェー
Publication of JP2024519529A publication Critical patent/JP2024519529A/ja
Publication of JP2024519529A5 publication Critical patent/JP2024519529A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023568007A 2021-05-06 2022-05-06 Ｃｄ１９特異的キメラ抗原受容体ｔ細胞療法 Pending JP2024519529A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESPCT/ES2021/070316 2021-05-06
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (2)

Publication Number Publication Date
JP2024519529A true JP2024519529A (ja) 2024-05-15
JP2024519529A5 JP2024519529A5 (cg-RX-API-DMAC10.html) 2025-05-15

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568007A Pending JP2024519529A (ja) 2021-05-06 2022-05-06 Ｃｄ１９特異的キメラ抗原受容体ｔ細胞療法

Country Status (11)

Country Link
US (1) US20240398945A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334357A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519529A (cg-RX-API-DMAC10.html)
AU (1) AU2022270952A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023061A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219214A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003299A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016940A2 (cg-RX-API-DMAC10.html)
JO (1) JOP20230269A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013088A (cg-RX-API-DMAC10.html)
WO (2) WO2022234158A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
US10221245B2 (en) * 2013-03-16 2019-03-05 Novartis Ag Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
WO2019137518A1 (zh) * 2018-01-15 2019-07-18 李华顺 以cd19为靶点的特异性抗体、car-nk细胞及其制备方法和应用
WO2019159193A1 (en) * 2018-02-13 2019-08-22 Indian Institute Of Technology Bombay Novel humanized anti-cd19 chimeric antigen receptor, its nucelic acid sequence and its preparation
WO2020180882A1 (en) * 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
US20200384023A1 (en) * 2017-12-06 2020-12-10 Abclon Inc. Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use Thereof
US20210069244A1 (en) * 2017-12-23 2021-03-11 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221245B2 (en) * 2013-03-16 2019-03-05 Novartis Ag Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
WO2014184143A1 (en) * 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
US20200384023A1 (en) * 2017-12-06 2020-12-10 Abclon Inc. Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use Thereof
US20210069244A1 (en) * 2017-12-23 2021-03-11 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
WO2019137518A1 (zh) * 2018-01-15 2019-07-18 李华顺 以cd19为靶点的特异性抗体、car-nk细胞及其制备方法和应用
WO2019159193A1 (en) * 2018-02-13 2019-08-22 Indian Institute Of Technology Bombay Novel humanized anti-cd19 chimeric antigen receptor, its nucelic acid sequence and its preparation
WO2020180882A1 (en) * 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL ONCOLOGY, vol. Volume 38, Issue 5, JPN6026020045, 9 December 2019 (2019-12-09), pages 415 - 422, ISSN: 0005869149 *

Also Published As

Publication number Publication date
CA3219214A1 (en) 2022-11-10
MX2023013088A (es) 2024-01-24
CL2023003299A1 (es) 2024-07-05
BR112023023061A2 (pt) 2024-01-30
EP4334357A1 (en) 2024-03-13
JOP20230269A1 (ar) 2023-10-26
US20240398945A1 (en) 2024-12-05
WO2022234134A1 (en) 2022-11-10
AU2022270952A1 (en) 2023-11-16
WO2022234158A1 (es) 2022-11-10
CO2023016940A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
US12534532B2 (en) CLL1-targeting antibody and application thereof
RU2748281C2 (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2022002550A (ja) Ｃｄ２０免疫療法のための組成物および方法
CN106554414A (zh) 抗cd19全人抗体以及靶向cd19的免疫效应细胞
WO2018121712A1 (zh) 一种新型嵌合抗原受体及其应用
CN107405362A (zh) 抗dll3嵌合抗原受体及其使用方法
US20230125234A1 (en) Anti cd44-ctla4 bispecific antibodies
IL316112A (en) Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
CA3216024A1 (en) Chimeric antigen receptor comprising an anti-her2 antibody or antigen-binding fragment thereof and natural killer cells comprising the same
KR20220152220A (ko) Ｃｄ19-지시된 키메라 항원 수용체 ｔ 세포 조성물 및 이의 방법 및 용도
AU2019387377A1 (en) Compositions and methods for treating cancer with anti-CD38 immunotherapy
US12492264B2 (en) Anti-ROR1 antibody and ROR1-targeting engineered cells
WO2023030539A1 (en) Anti-gpc3 chimeric antigen receptor and methods of use thereof
TW202502363A (zh) 用於治療全身性自體免疫疾病之細胞療法
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
US20250064853A1 (en) Anti-cd84 antibodies and chimeric antigen receptors
US20240384293A1 (en) Viral vector production system
TW202340456A (zh) 靶向ｈｉｖ感染細胞的嵌合抗原受體ｔ細胞
US20240398945A1 (en) Cd19-specific chimeric antigen receptor t-cell therapy
IL293393A (en) Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
TWI825131B (zh) Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法
US12109237B2 (en) S309 chimeric antigen receptors and methods of use
WO2025217843A1 (en) Car with improved intracellular domain
HK40104616A (en) Anti-gpc3 chimeric antigen receptor and methods of use thereof
KR20240082201A (ko) B7-h3 키메라 항원 수용체 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231128

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20231228

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20231128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260803